Genome Editing– tag –
-
CRISPR Gene Therapies Expand in 2026: EDIT-101 for Retinitis Pigmentosa Gains FDA Accelerated Approval, Following Casgevy for Sickle Cell Disease
Ubie Doctor's Note Japan Overview By 2026, CRISPR-based gene therapies are rapidly expanding, with EDIT-101 for retinitis pigmentosa receiving FDA accelerated approval in late 2025, building on the 2023 approval of Casgevy for sickle cel... -
CRISPR Gene Therapies Expand Beyond Initial FDA Approvals, Advancing to Late-Stage Trials for Diverse Indications
Ubie Doctor's Note USA Overview As of mid-2026, two CRISPR gene therapies, Casgevy (for sickle cell disease and beta-thalassemia) and EDIT-101 (for Leber congenital amaurosis type 10), have received FDA approval, establishing foundationa... -
Strategic Capital Influx in Gene Therapy: Pfizer Invests in CRISPR Biotech, AstraZeneca Strengthens China Cell Therapy Capabilities
BioPharma Dive USA Overview The gene therapy sector is experiencing a surge in strategic funding and M&A activities from major pharmaceutical companies. Pfizer has invested in CRISPR biotech Caribou Biosciences, while AstraZeneca pla... -
Vertex’s CRISPR Gene Therapy CASGEVY Gains Expanded FDA Approval for Sickle Cell Disease and Beta Thalassemia in Children Ages 2 and Older
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced the US FDA has approved an expanded indication for its gene therapy, CASGEVY® (exagamglogene autotemcel), for treating sickle cell disease or transfusion-dependent beta... -
Amerigo Scientific Unveils Advanced iPSC-Derived Cells to Propel Biomedical Research and Cell Therapy
24-7PressRelease.com (Amerigo Scientific発表) USA Overview Amerigo Scientific has launched a new portfolio of high-purity, iPSC-derived cells, including advanced reporter lines, aimed at accelerating biomedical research and cell therapy ... -
FDA RMAT Designations Reach 162 Total: Rocket Pharmaceuticals and CRISPR Therapeutics Lead
BioInformant USA Overview The FDA's publicly announced Regenerative Medicine Advanced Therapy (RMAT) designations have reached a total of 162, with approximately half of all RMAT applications being approved, according to BioInformant dat... -
HCA Healthcare Announces Promising Results for CRISPR Gene Therapy Exa-cel in Pediatric Sickle Cell Disease and Beta-Thalassemia Patients
HCA Healthcare USA Overview HCA Healthcare has announced findings from a New England Journal of Medicine study, sponsored by Vertex Pharmaceuticals, demonstrating that the CRISPR gene-editing therapy exa-cel shows promising results in pe... -
CRISPR’s First Clinical Evidence for HBV cccDNA Elimination, Prime Editing Advances to Inaugural Human Trial
CRISPR Medicine News USA Overview Precision Biosciences' PBGENE-HBV has demonstrated the first clinical evidence of eliminating viral cccDNA in chronic Hepatitis B patients, marking a significant milestone for CRISPR-based therapies in i... -
Long-Read DNA Sequencers Market to Accelerate by 2035 Amid Biopharma Quality Control Demand: Essential for CAR-T Genomic Evaluation
IndexBox News and Statistics Global Overview The long-read DNA sequencer market is projected for accelerated growth by 2035, driven by biopharmaceutical quality control demands, particularly the need for high-resolution genomic evaluatio... -
Top 10 Emerging Healthcare Technologies in 2026: CRISPR Gene Editing Established as Therapeutic Category, Regenerative Medicine Nearing Clinical Application
Slate USA Overview An article on 10 emerging healthcare technologies to watch in 2026 highlights that CRISPR gene editing is moving beyond the lab to become a bona fide therapeutic category. Additionally, regenerative medicine and stem c...
